Can molecular markers revolutionize adrenal cancer management?

NCT ID NCT05754892

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to bring molecular markers into routine care for patients with rare adrenal cancers. Researchers will collect blood, urine, and tumor samples from 450 patients before and after surgery to see if these markers can guide treatment decisions. The goal is to make these tests a standard part of follow-up, potentially improving how doctors monitor and treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could make molecular testing a standard part of adrenal cancer care, helping doctors better predict outcomes and choose treatments.
What could go wrong: This is an observational study, not a treatment trial. The markers have been validated in the lab but may not improve patient outcomes in real-world practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal cortex carcinoma cancer malignant adrenal gland pheochromocytoma neoplasm paraganglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL CANCER

Contacts and locations

Locations

GH Paris Centre, Assistance Publique - Hôpitaux de Paris
RECRUITING

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.